AIM VACCINE (06660) has submitted a registration application for the market of its iterative process high-potency human diploid rabies vaccine, leading in technical advantages.

AIM VACCINE (06660) announced on August 24 that the company has submitted a market registration application for its self-developed high-titer human diploid rabies vaccine using an iterative process to the National Medical Products Administration. This competitively positioned rabies vaccine is nearing registration and will be part of a product portfolio alongside IMU's serum-free iterative rabies vaccine and Vero cell rabies vaccine, aiming to seize a market advantage. According to the results of a completed unblinded Phase III clinical trial, IMU's high-titer human diploid rabies vaccine demonstrates good safety, immunogenicity, and lasting immunity, with its immunogenicity and durability outperforming similar control vaccines, achieving all predetermined evaluation criteria for clinical trials. Wu Jin-nan, the Honorary General Manager of IMU, has publicly stated, I am very confident in this human diploid rabies vaccine. It should have the most advanced production process in China, the best quality in terms of potency and safety, and be the most convenient rabies vaccine for injection. Faced with fierce market competition, Wu Jin-nan believes that new opportunities lie within the immunization schedule, namely how many doses and how long. Currently, the immunization schedule for rabies vaccines on the market is largely completed within three to four weeks, with significant room for optimization in administration methods. AIM VACCINE's product can use a simple four-dose or 2-1-1 four-dose schedule, which could enhance patient compliance. Based on this, its competitive strength and development potential are promising. Rabies is a disease with a very high mortality rate, approaching 100% once symptoms appear. At present, there are no effective methods for treating rabies in clinical practice, making prevention a long-term necessity. As the world's second-largest rabies vaccine supplier, IMU is committed to leading the deep technological iteration and upgrade of rabies vaccines globally, providing better quality and safer series of rabies vaccine products, thereby further consolidating the companys leading position in the global rabies vaccine market. With the approval of the high-titer human diploid rabies vaccine, it will create synergy with the existing series of rabies vaccines, enhancing the core competitiveness of the companys rabies vaccine products and consolidating its leading position. Meanwhile, as part of its global layout, it can contribute additional revenue, strengthen IMU's market position, and add new momentum for its sustained and stable development.